Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals (Nasdaq: KALV) granted inducement stock options to five newly hired employees totaling 66,375 shares on April 1, 2026. Options exercise price will equal the first reported closing price after the grant date. One-fourth vests after one year; remaining vest monthly over three years. Each option has a 10-year term and is governed by the company’s Inducement Equity Incentive Plan and individual option agreements, and the grants comply with Nasdaq Listing Rule 5635(c)(4).
KalVista (Nasdaq: KALV) reported positive interim Phase 3 KONFIDENT-KID results for EKTERLY (sebetralstat) in children aged 2-11.
Among 172 treated HAE attacks in 33 pediatric participants (data cut Dec 15, 2025): mean 0.7 attacks treated/patient/month, median time to treatment 25 minutes (67% within 1 hour), 88.9% mild/moderate. In the 150 mg cohort median symptom relief was 1.5 hours and complete resolution 12 hours. Sebetralstat was well tolerated with no serious or treatment-related adverse events and no swallowing issues. Enrollment finished one year early; KalVista expects a US NDA in Q3 2026 and a 2027 launch if approved.
KalVista Pharmaceuticals (Nasdaq: KALV) reported results for the eight months ended December 31, 2025, following a fiscal-year change. EKTERLY generated $49.1 million global net product revenue since launch and recorded 1,702 US patient start forms through February 28, 2026 (about 20% of the US patient population).
Key clinical progress includes completed pediatric Phase 3 enrollment and planned US NDA filing in Q3 2026; cash and marketable securities were approximately $300.2 million at year-end.
KalVista Pharmaceuticals (Nasdaq: KALV) will present five abstracts, including a late-breaking oral poster, at the 2026 Global Angioedema Leadership Conference in Madrid from March 26–29, 2026.
The late-breaking oral is an interim analysis of KONFIDENT-KID evaluating sebetralstat for on-demand treatment of hereditary angioedema attacks in children aged 2–11, plus four KONFIDENT-S and patient-survey posters.
KalVista Pharmaceuticals (Nasdaq: KALV) will host a conference call and webcast on March 25, 2026 at 8:30 a.m. ET to review eight months fiscal year 2025 financial results and provide a corporate update. The live webcast and an archived replay will be available on the company investor website.
KalVista Pharmaceuticals (NASDAQ: KALV) reported inducement option grants for a newly hired employee: an aggregate of 6,750 options granted on March 1, 2026, under Nasdaq Listing Rule 5635(c)(4). Exercise price will equal the first reported closing price after the grant. Options vest 25% after one year, then monthly over three years, have a 10-year term, and are governed by the company's Inducement Equity Incentive Plan and a stock option agreement.
KalVista (Nasdaq: KALV) reported new clinical data showing high patient satisfaction and shifting treatment behavior with oral EKTERLY (sebetralstat). In KONFIDENT-S, patients treated 2,464 attacks with sebetralstat; 83.1% of treated attacks rated satisfied or better and use of injectables fell with repeated use.
Analyses showed treating within 30 minutes predicted faster symptom relief, with simulations suggesting nearly 90% might experience relief within 12 hours.
KalVista Pharmaceuticals (Nasdaq: KALV) will present fireside chats at two investor conferences in March 2026. The company will speak at TD Cowen on March 4, 2026 at 11:10 a.m. EST and at Citizens Life Sciences on March 11, 2026 at 10:45 a.m. EST.
According to the company, live audio webcasts will be available on the Investors section of its website, with archived replays posted about two hours after each event.
KalVista (Nasdaq: KALV) said the new International Pediatric HAE Guideline recommends EKTERLY (sebetralstat) as a first-line on-demand therapy for acute hereditary angioedema attacks in adolescents aged 12 and older.
The guideline cites robust clinical evidence, notes EKTERLY is the first oral on-demand option for 12+, follows seven global approvals in 2025, and highlights ongoing pediatric development with an NDA for ages 2–11 on track for Q3 2026.
KalVista Pharmaceuticals (Nasdaq: KALV) announced the acceptance of three abstracts for presentation at the 2026 AAAAI Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026. Two poster sessions are scheduled Friday, Feb 27 (2:45–3:45 pm ET) and one late-breaking poster on Sunday, Mar 1 (9:45–10:45 am ET).
Titles include placebo‑controlled response drivers, on‑demand treatment patterns from KONFIDENT‑S, and an investigator‑initiated ECRINS survey on attack management and burden. Links to presentations will be available on the company website under Publications.